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Abstract
Background: wLocal failure is an important cause of morbidity and mortality in nasopharyngeal
carcinoma (NPC). Although surgery or brachytherapy may be feasible in selected cases, most
patients with local failure require external beam re-irradiation. Stereotactic radiation using single
or multiple fractions have been employed in re-irradiation of NPC, but the optimal fractionation
scheme and dose are not clear.
Methods:  Records of 125 NPC patients who received salvage stereotactic radiation were
reviewed. A matched-pair design was used to select patients with similar prognostic factors who
received stereotactic re-irradiation using single fraction (SRS) or multiple fractions (SRM). Eighty-
six patients were selected with equal number in SRS and SRM groups. All patients were individually
matched for failure type (persistent or recurrent), rT stage (rT1-2 or rT3-4), and tumor volume (≤
5 cc, >5–10 cc, or >10 cc). Median dose was 12.5 Gy in single fraction by SRS, and 34 Gy in 2–6
fractions by SRM.
Results: Local control rate was better in SRM group although overall survival rates were similar.
One- and 3-year local failure-free rates were 70% and 51% in SRS group compared with 91% and
83% in SRM group (p = 0.003). One- and 3-year overall survival rates were 98% and 66% in SRS
group compared with 78% and 61% in SRM group (p = 0.31). The differences in local control were
mainly observed in recurrent or rT2-4 disease. Incidence of severe late complications was 33% in
SRS group vs. 21% in SRM group, including brain necrosis (16% vs. 12%) and hemorrhage (5% vs.
2%).
Conclusion: Our study showed that SRM was superior to SRS in salvaging local failures of NPC,
especially in the treatment of recurrent and rT2-4 disease. In patient with local failure of NPC
suitable for stereotactic re-iradiation, use of fractionated treatment is preferred.
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Background
Local recurrence is an important cause of treatment failure
in nasopharyngeal carcinoma (NPC). Recent advances in
radiotherapy planning and delivery and the use of concur-
rent chemo-radiotherapy have significantly reduced the
incidence of local failure in NPC, and most modern series
reported an overall 5-year local control rate of 76–91% [1-
5]. In patients with advanced T stage and/or bulky tumor,
local failure however remains an important cause of mor-
bidity and mortality. Although surgical resection or brach-
ytherapy can be used as salvage treatment in selected cases
of local failure, most patients require external re-irradia-
tion for retreatment of NPC. Conventional two-dimen-
sional radiotherapy planning and delivery was commonly
used in the past for external reirradiation of NPC, but
treatment outcome was generally poor with a high inci-
dence of severe late complications [6-8]. Three-dimen-
sional conformal radiotherapy can achieve better target
coverage and sparing of critical structures, but the inci-
dence of late complication still appears to be high after
reirradiation of NPC even with the use of conformal radi-
otherapy [9]. The technique of stereotactic localization of
target and treatment delivery has also been employed in
salvaging local failures of NPC, which includes the use of
single fraction of stereotactic re-irradiation (SRS) or mul-
tiple fractions of stereotactic re-irradiation (SRM). These
two techniques were employed at Queen Mary Hospital in
Hong Kong and Sun Yat Sen University Cancer Center in
Guangzhou for re-irradiation of NPC, with adoption of
SRS in the former center and SRM in the latter one. Differ-
ent techniques were adopted at the two centers due to
institutional preference and logistic reasons such as avail-
able machine time. Since there were no prospective stud-
ies comparing stereotactic re-irradiation using SRS or
SRM, we conducted a retrospective study to compare the
outcome of patients treated by SRS and SRT using a
matched-pair design.
Methods
Selection of matched pair
This was a retrospective study comparing the outcome of
patients with locally recurrent NPC treated by SRS and
SRM. Records of patients who received SRS or SRM as sal-
vage treatment of NPC at Queen Mary Hospital in Hong
Kong and Sun Yat-Sen University in Guangzhou were
reviewed for inclusion into the study. A matched pair
study was used to select and analyze patients with similar
prognostic factors from the two treatment groups. Only
those patients who satisfied the following criteria were
included in the matching process: history of poorly differ-
entiated or undifferentiated carcinoma of the nasophar-
ynx, completed a course of radical radiotherapy with or
without chemotherapy, and histological proven local fail-
ure or progression of local disease documented by serial
imaging. Patients who received SRS or SRM as a planned
boost after external radiotherapy and those with disease
elsewhere were excluded.
Individual patients from the two treatment groups were
matched for important prognostic factors identified from
previous studies: type of local failure (persistent disease,
defined as local failure that occurred within 6 months of
completion of primary radiotherapy, vs. recurrent disease,
defined as local failure that occurred beyond 6 months of
completion of primary radiotherapy), retreatment T stage
(rT1-2 vs. rT3-4), and tumor volume (≤ 5 cc vs. > 5 – 10 cc
vs. > 10 cc). Each patient in the SRS group was matched
with another patient in the SRM group with respect to
these factors, and only patients that were matched for all
3 factors were included in the study.
Patient characteristics
Forty-eight patients received SRS at Queen Mary Hospital
from January 1994 to June 2005 and 90 patients received
SRM at Sun Yat-Sen University Cancer 2005 and 90
patients received SRM at Sun Yat-Sen University Cancer
Center from September 1999 to December 2005 for iso-
lated local failures of NPC. Thirteen patients were not
included in the matching process due to presence of syn-
chronous nodal disease in 2 and distant metastases in 3,
and the use of SRS/SRM as planned boost in 8. The
remaining 125 patients were included in the matching
process, and 43 matched pairs were selected for compari-
son. All these patients had undifferentiated type of
nasopharyngeal carcinoma and were staged by computed
tomography and magnetic resonance imaging at the time
of diagnosis. First course of radiotherapy was delivered
using megavoltage radiotherapy with conventional two-
dimensional technique, and the dose to nasopharynx was
66–70 Gy. About 23% of patients from Queen Mary Hos-
pital and 26% from Sun Yat-Sen University Cancer Center
also received adjunctive chemotherapy. All patients were
jointly assessed by radiation oncologist and head and
neck surgeon for other options including nasopharyngec-
tomy and brachytherapy prior to stereotactic radiother-
apy. Table 1 summarizes the patient characteristics of
matched SRS and SRM groups.
SRS and SRM treatment
SRS was performed at Queen Mary Hospital using the
commercial XKnife system (Radionics, Burlington, MA) to
deliver multiple non-coplanar arcs of photon to the target
with a modified 6 MV linear accelerator (Varian Clinac
600C, Milpitas, CA.). Head immobilization and target
localization were performed with the Brown-Roberts-
Wells head frame and stereotaxic system (Radionics, Bur-
lington, MA). Axial contrast CT with a slice thickness of
2.5 to 3 mm was performed for treatment planning, sup-
plemented by axial contrast MR with a slice thickness of 3
mm in rT3-4 disease. Target volume was defined as anyHead & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
Page 3 of 10
(page number not for citation purposes)
abnormal soft-tissue mass and/or contrast-enhancing
areas as shown in axial imaging plus a margin of about 2–
3 mm. In most patients (43%), the target was covered by
single isocenter using 3 to 5 arcs of beams with a degree of
90 to 210. Median dose was 12.5 Gy prescribed to 80%
isodose line, with a range of 8 to 18 Gy. Figure 1 shows
isodose coverage of tumor in a patient treated by SRS.
SRM was performed at Sun Yat-Sen University Cancer
using a commercial stereotactic radiotherapy system
(Creat, China) to deliver multiple arcs of photon with a
modified 8-MV linear accelerator (Elekta, Sweden). All
patients were immobilized using a relocatable head ring
and bracket with a plastic mask to cover whole head. Axial
contrast-enhanced computed tomography (CT) scan with
a slice thickness of 3 mm was performed for treatment
planning. Majority of patients only had CT performed for
localization of target/critical structures and planning since
MRI was not available in the center in Guangzhou before
2003. Target volume was defined by abnormal contrast-
enhanced mass plus a margin of about 2 – 3 mm. The tar-
get volume was usually covered by one isocenter (98%)
using four to six arcs with a degree of 30 – 150. SRT was
carried out using single fraction per day and 2 – 3 fractions
per week, with an inter-fractional interval of at least 1 day.
Median dose was 18 Gy prescribed to 90% isodose line
(range: 10 – 24 Gy) in 2 to 4 fractions for persistent dis-
ease, and 48 Gy to 90% isodose line (range: 20 – 49 Gy)
in 4 – 6 fractions for recurrent disease. Figure 2 shows the
isodose coverage of tumor in a patient treated by SRM.
Response assessment and follow-up
Nasopharyngoscopy +/- biopsy and imaging were per-
formed at 8–12 weeks after treatment to document local
disease status. Patients with controlled local disease were
regularly followed up every 2–3 months in the first year
Table 1: Characteristics of patients treated by stereotactic reirradiation using single and multiple fractions and for local failures of 
nasopharyngeal carcinoma
Stereotactic radiotherapy with single 
fraction
(n = 43)
Stereotactic radiotherapy with multiple 
fractions
(n = 43)
All
(n = 86)
Gender
Male 32 (74%) 35 (81%) 67 (78%)
Female 11 (26%) 8 (19%) 19 (22%)
Age
≤ 45 21 (49%) 21 (49%) 42 (49%)
> 45 22 (51%) 22 (51%) 44 (51%)
median (range)/years 46 (32–84) 46 (18–69) 46 (18–84)
Type of failure
Persistent disease 19 (44%) 19 (44%) 38 (44%)
Recurrent disease 24 (56%) 24 (56%) 48 (56%)
Retreatment T stage
rT1 25 (58%) 23 (54%) 48 (56%)
rT2 5 (12%) 7 (16%) 12 (14%)
rT3 9 (21%) 6 (14%) 15 (17%)
rT4 4 (9%) 7 (16%) 11 (13%)
Time from 1st course of radiotherapy to 
reirradiation
≤ 12 months 23 (53%) 24 (56%) 47 (55%)
> 12 – 24 monhts 3 (7%) 8 (18%) 11 (13%)
> 24 – 48 months 6 (14%) 6 (14%) 12 (14%)
> 48 months 11 (26%) 5 (12%) 16 (18%)
median (range)/months 10 (3 – 197) 10 (3 – 107) 10 (3 – 197)
Tumor volume
≤ 5 cc 21 (49%) 21 (49%) 42 (49%)
> 5 – 10 cc 13 (30%) 13 (30%) 26 (30%)
> 10 cc 9 (21%) 9 (21%) 18 (21%)
median (range)/cc 5.1 (1.3 – 30.7) 5.6 (0.8 – 24.7) 5.2 (0.8 – 30.7)Head & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
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and every 3–4 months thereafter. Computed tomography
and/or magnetic resonance imaging were performed at
least annually for 3 years after treatment.
Statistical analysis
Categorical variables were compared using chi square test
or Fisher's exact test as appropriate, and continuous varia-
bles were compared using Student's t test. Treatment out-
come of SRS and SRM groups were compared using the
following endpoints: local failure-free rate, nodal failure-
free rate, distant failure-free rate, failure-free rate and over-
all survival rate. The endpoints were analyzed using the
product-limit method of Kaplan and Meier, and time was
measured from the date of SRS or SRM until time of event
occurrence, or most recent follow-up for censored obser-
vations. In patients with complete regression of disease
after SRS or SRT, local failure was defined based on posi-
tive biopsy and/or radiological evidence of relapse. In
patients who failed to achieve complete regression of dis-
ease after salvage treatment, local failure-free interval was
set to zero. Likewise, neck node recurrence was used to
define nodal failure-free rate, distant metastases was used
to define distant failure-free rate, and any failure (loco-
regional or distant) was used to define failure-free rate. In
determining overall survival rate, event was defined as
deaths due to any cause. Actuarial curves were compared
between SRS and SRM groups and the significance of dif-
ferences was calculated using log rank test, a p value less
than 0.05 was considered to be statistically significant.
Results
Tumor control and survival
Median follow-up time for surviving patients was 40
months (range: 3 – 106) after SRS and 24 months (range:
5 – 77) after SRM. Local control was significantly better in
patients treated by SRM: 1- and 3-year local failure-free
rates were 91% and 83% in SRM group compared with
70% and 51% in SRS group (p = 0.003; Figure 3). Nodal
relapse was uncommon after salvage treatment in both
groups: 3-year nodal-failure free rates in SRM and SRS
group were 96% and 85%, respectively (p = 0.19). SRM
group had a higher incidence of distant metastases after
treatment compared with SRS group, 3-year distant fail-
ure-free rate was 69% in the former compared with 82%
in the latter, but the difference was not significant (p =
0.089). No significant difference in failure-free rate was
observed between the two groups: 1- and 3-year failure-
free rates were 75% and 52% in SRM group compared
with 62% and 43% in SRS group (p = 0.20). There was
also no significant difference in overall survival between
the two groups: 1- and 3-year overall survival rates were
78% and 61% in SRM group compared with 98% and
66% in SRS group (p = 0.31; Figure 4).
Isodose curve showing coverage of the tumor in right side of  nasopharynx in a patient treated by single fraction of stereo- tactic radiotherapy (target: green arrow; 80% isodose line:  red arrow) Figure 1
Isodose curve showing coverage of the tumor in right 
side of nasopharynx in a patient treated by single 
fraction of stereotactic radiotherapy (target: green 
arrow; 80% isodose line: red arrow).
Isodose curve showing coverage of the tumor in right side of  nasopharynx in a patient treated by multiple fractions of ster- eotactic radiotherapy (target: green arrow; 90% isodose line:  red arrow) Figure 2
Isodose curve showing coverage of the tumor in right 
side of nasopharynx in a patient treated by multiple 
fractions of stereotactic radiotherapy (target: green 
arrow; 90% isodose line: red arrow).Head & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
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Complications
Both SRS and SRM were well tolerated with no severe
acute complications. The incidence of severe late compli-
cations was higher in SRS group compared with SRM
group (33% vs. 21%), although the difference was not sta-
tistical significant (p = 0.22). Brain necrosis occurred in 7
patients after SRS (16%) and 5 patients after SRT (12%),
with 2 fatal outcome. Massive heamorrhage occurred in 2
patients after SRS (2%) and 1 patient after SRM (4%),
with 1 fatal outcome. Altogether there were 3 treatment-
related deaths, all occurred in the SRM group.
Subgroup analysis
We further analyzed the outcome after SRS and SRM in
different subgroups according to important prognostic
factors, and the results are summarized in Table 2. The dif-
ference in local control between SRS and SRM group was
mainly seen in patients treated for recurrent disease and
those with disease extended beyond nasopharynx. In
patients with persistent disease as well as those with dis-
ease confined to nasopharynx, there was no significant
difference in local control after SRS or SRM (Figure 5 &6).
No differences in survival rates were observed in all sub-
groups, including those with significant differences in
local control rates favoring SRT group.
Discussion
Aggressive treatment of local failure of NPC is generally
recommended since a significant proportion of patients
can still be successfully salvaged and long-term survivors
are not uncommon with reported 5-year survival rates
ranging from 54% after surgery [10] to 60–77% after
brachytherapy [11,12]. Although surgery and brachyther-
apy can produce excellent results, only selected cases of
local failure of NPC with disease confined to nasopharynx
are amenable to these treatments. Most patients with local
failure of NPC require external beam radiotherapy but
treatment results after re-irradiation using conventional
technique remained poor. The reported five-year survival
rates after external reirradiation ranged from 7.6% to 36%
with the use of conventional two-dimensional treatment
planning and radiotherapy (6–8), and 12.4% in a mixed
cohort of patients treated either with conventional two-
dimensional or three-dimensional conformal radiother-
apy [13]. A high incidence of late complication was com-
monly observed after external beam reirradiation,
Local control curves Figure 3
Local control curves. comparison of local failure-free probabilities in patients with local failures of nasopharyngeal carcinoma 
treated by stereotactic radiotherapy using single or multiple fractionsHead & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
Page 6 of 10
(page number not for citation purposes)
majority being neurological damage and soft tissue fibro-
sis. In a cohort of patients with local failure of NPC and
all received re-irradiation by three-dimensional confor-
mal technique, the incidence of severe late complications
was still high with 5-year actuarial incidence of 100% for
≥ grade 3 toxicity and 49% for ≥ grade 4 toxicity (9).
The concept of applying SRS in the retreatment of NPC is
attractive due to the frequent involvement of intracra-
nium and base of skull in NPC and the general radiosen-
sitivity of the tumor. There were several published reports
of retreatment of NPC by SRS and the reported tumor con-
trol rates ranged from 53 to 86% [14-20], but most of
these were small series with a relatively short follow-up. In
a previous report based on patients treated by SRS at
Queen Mary Hospital, 5-year local failure-free and overall
survival rates were 47.2% and 46.9%, respectively [21].
Neuroendocrine complications occurred in 27% of
patients but there were no treatment-related deaths. The
results of that report compared favorably with that of gold
grain implantation based on outcome of patients treated
at the same institution [22].
Based on radiobiology principle, fractionation will pro-
vide better therapeutic ratio and improve treatment out-
come in retreatment of NPC, and SRM has subsequently
been explored as a salvage treatment for NPC. Mitsuhashi
et al treated 3 patients with rT1 NPC using SRM at a dose
of 50–64 Gy, and all 3 patients achieved complete
response and remained free of local disease at 4–61
months [23]. The report by Mitsuhashi et al also included
another patient with mucoepidermoid carcinoma of the
nasopharynx treated by SRM after previous two courses of
external radiotherapy, but the treatment was complicated
by rupture of the internal carotid artery resulting in
patient death. Using SRM at a dose of 24 Gy in 2 to 4 frac-
tions, Orecchia et al reported a less satisfactory outcome
in 13 patients with locally recurrent NPC, with a 3-year
survival rate of 31% [24]. Ahn et al treated 12 patients
with recurrent NPC by SRM using a median dose of 54 Gy,
Survival curves: comparison of overall survival probabilities in patients with local failures of nasopharyngeal carcinoma treated  by stereotactic radiotherapy using single or multiple fractions Figure 4
Survival curves: comparison of overall survival probabilities in patients with local failures of nasopharyngeal 
carcinoma treated by stereotactic radiotherapy using single or multiple fractions.Head & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
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and reported a 2-year local control rate of 92% [25]. Yau
et al compared the outcome of 52 patients with NPC
treated by either brachytherapy or SRT for persistent dis-
ease, and observed a better tumor control after SRM [26].
Xiao et al reported the outcome of 50 patients with per-
sistent or recurrent nasopharyngeal carcinoma treated by
SRM with a dose ranged from 14 to 35 Gy using a fraction
dose of 5 to 15 Gy [27]. Of the 31 evaluable patients with
persistent disease, 94% had complete response with a
one-year disease-free survival rate of 47%. Eighteen
patients, most of them had rT3-4 tumor, were treated for
recurrent disease. The complete response rate was 56%
and 1-year disease-free survival rate was 47%. In Xiao's
series, however, 16% of patients treated by SRM devel-
oped fatal haemorrhage, probably due to the relatively
high cumulative dose delivered. The largest published
series was from the primary data set of 90 SRT patients
used for the current study [28]. The reported 3-year local
control rate was 89% for persistent disease and 19% for
recurrent disease. Three-year disease-specific survival rate
was 58%. The incidence of severe late complications was
19% and there were 3 treatment-related deaths.
Based on matched-pair data from the two largest reported
SRS and SRM series for NPC, we demonstrated superior
tumor control with SRM, but survival rates were similar.
Possible explanations include different follow-up dura-
tion in the two groups, the higher incidence of treatment-
related deaths in SRM group, the use of additional salvage
treatments, and different failure patterns. In SRM groups,
no additional radiotherapy was given after local failure
due to the high cumulative dose, whereas in SRS group,
additional radiotherapy was given whenever possible after
documented treatment failure. Thus the use of second sal-
vage treatment may partly account for comparable sur-
vival rates in the two groups. In addition, patients in SRM
group had a higher incidence of distant metastases than
SRS group probably related to the percentage of higher N
stage in the former group, and the survival benefits
obtained with improved local tumor control were likely to
be offset by the occurrence of distant metastases.
Late complications are common in patients receiving re-
irradiation for NPC. In view of the high radiation dose
already received by patients during prior radiotherapy and
Persistent disease: comparison of local failure-free probabilities in subgroup of patients with persistent disease Figure 5
Persistent disease: comparison of local failure-free probabilities in subgroup of patients with persistent disease.Head & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
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the presence of numerous nearby critical structures, it is
unrealistic to expect any new form of re-irradiation to be
totally risk-free. Late complications, however, differ signif-
icantly in terms of incidence and severity among different
techniques of re-irradiation. In general, patients with
bulky disease and tumor extended beyond nasopharynx
usually have a higher incidence of late complications.
When patients with similar tumor extent and size are
being considered, SRS or SRM usually leads to lower inci-
dence of late complications compared with other tech-
niques because of high dose conformity to the target. One
severe and highly fatal complication that can occur after
re-irradiation is massive hemorrhage in the nasopharynx,
sometimes leading to fatal outcome. The reported inci-
dence of severe hemorrhage after SRS or SRM was rela-
tively high compared to other re-irradiation techniques.
Possible causes of severe hemorrhage after re-irradiation
include mucosal necrosis, tumor progression, and carotid
aneurysm. The latter one is an important cause of uncon-
trolled bleeding which should not be overlooked. In order
to reduce the risk of hemorrhage as a result of carotid
aneurysm/rupture following re-irradiation, careful selec-
tion of patients and treatment planning are important.
Patients with direct tumor encasement of cavernous sinus
and internal carotid artery should not be treated by SRS,
and the dose to carotid artery should be minimized in all
cases. Dose per fraction is also important and most hem-
orrhage occurred after SRS or SRM using large fractional
dose. In patients with tumor encasement of carotid artery,
SRM instead of SRS should be used for reirradiation, and
a small fractional dose not exceeding 6 Gy is recom-
mended.
The superior tumor control rate achieved by SRM is likely
due to the higher dose that can be delivered using this
technique compared with SRS. Several reirradiation series
have also recognized the important relationship between
reirradiation dose and treatment outcome, although the
optimal dose is not yet defined. Wang observed reirradia-
tion dose ≥ 60 Gy was associated with improved survival,
although most patients received high dose radiotherapy
in his series had rT1-2 stage [29]. Similarly, Öksüz et al
also reported improved local control and survival after
reirradiation with a dose of 60 Gy than < 60 Gy [30]. Lee
et al also reported improved survival when a reirradiation
dose > 60 Gy was used [31]. Teo et al however reported
rT1 tumor: comparison of local failure-free probabilities in subgroup of patients with disease confined to nasopharynx Figure 6
rT1 tumor: comparison of local failure-free probabilities in subgroup of patients with disease confined to 
nasopharynx.Head & Neck Oncology 2009, 1:13 http://www.headandneckoncology.org/content/1/1/13
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poor survival and high incidence of complications after
high dose (≥ 60 Gy) reirradiation of NPC with radical
intent, although the survival was still better than those
treated with palliative intent using a lower dose of 40–50
Gy [32]. In all these series, retreatment was primarily car-
ried out using conventional two-dimensional radiother-
apy. In a cohort of 186 NPC patients reirradiated with
either conventional or conformal radiotherapy, Chang et
al observed that reirradiation dose ≥ 50 Gy yielded better
survival [13]. Using intensity-modulated radiotherapy, Lu
et al [33] reported excellent local control rate after high
dose (68–70 Gy) retreatment of NPC, although the fol-
low-up time in that study was still short for evaluation of
late complications. In another series of reirradiation of
NPC also using intensity-modulated radiotherapy, a dose
range between 50–60 Gy yielded good tumor control for
rT1-3 NPC but not for rT4 disease [34]. Based on these
reports, a dose of at least 50 Gy should be delivered using
SRM for local failure of NPC, although the optimal frac-
tionation schedule is still not clear. In patients with per-
sistent disease, especially those with small volume disease
confined to nasopharynx, a lower dose may be used judg-
ing from the results of SRS.
Conclusion
In conclusion, our study showed that SRM was superior to
SRS in salvaging local failures of NPC, especially in
patients with recurrent disease and tumor extended
beyond nasopharynx. In patients with local failure of
NPC, stereotactic re-irradiation using multiple fractions
rather than single fraction to deliver a higher total is pre-
ferred.
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